Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2021-12-23 13:35:04
Oslo, 23 December 2021 - Navamedic ASA (OSE: NAVA) today announces a trading
update based on updated revenue growth expectation for the full-year 2021 of
around 30%, compared to the previously communicated annual growth target of 20%.
The revenue growth is driven by strong performance in Q4 with a particularly
strong December month.
Reference is made to Navamedic's communicated target of 20% annual growth for
2021. As the company's preliminary financial results for Q4, and hence the full
year 2021, represent a noticeable improvement compared to the communicated
target for 2021, the company has decided to provide a trading update based on an
updated revenue growth expectation for the full-year 2021 of around 30%.
"Our portfolio of specialty pharma and consumer health products continues to
grow with particularly strong performance for the obesity product Mysimba. The
growth in the fourth quarter and December in particular has been stronger than
expected. We are pleased to see this development, and to provide an updated
revenue growth expectation for the full year 2021 compared to 2020 of around
30%," says Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic
ASA.
Navamedic wants to reiterate that that the books for Q4 2021 are not closed,
that the revenue growth in 2021 thus at this stage is an estimate and that the
final numbers will be communicated on Navamedic's presentation of the Q4 numbers
on February 17, 2022.
Going into 2022, Navamedic maintains its annual growth target of 20% and its mid
-term ambition of building a NOK 500 million company through organic growth with
strong gross margins and underlying profitability.
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. The information was
submitted for publication, through Newsweb by Lars Hjarrand at 13:34 hrs CET on
23 December 2021.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47917 62842
E-mail: lars.hjarrand@navamedic.com
About
Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visitwww.navamedic.com